Evidence-Based Decision Aid for Patients With Parkinson Disease: Protocol for Interview Study, Online Survey, and Two Randomized Controlled Trials

Abstract

Background: Shared decision making is particularly important in situations with different treatment alternatives. For the treatment of idiopathic Parkinson disease, both pharmacological and surgical approaches can be applied.

Objective: In this research project, a series of studies will be conducted to investigate how decision aids for patients with idiopathic Parkinson disease should be designed in order to support the decision-making process.

Methods: In Study 1a, qualitative interviews will be conducted to determine which needs frequently occur for patients with idiopathic Parkinson disease. In Study 1b, the identified needs will then be rated for personal relevance by an independent group of patients in an online survey. In Study 2, a randomized controlled trial will be used to pretest different decision aids in a sample group of people who do not have a medical background and who do not have Parkinson disease. In Study 3, a randomized controlled trial will be used to investigate the effect of the decision aids that had been evaluated as positive in Study 2 with patients who have idiopathic Parkinson disease.

Results: This series of studies received ethical approval in January 2020. As of June 2020, data collection for Study 1a has started, and it is estimated that Studies 1a, 1b, 2, and 3 will take approximately 4, 4, 6, and 6 months to complete, respectively. It is planned to present the results and analyses at international conferences and to submit the results to peer-reviewed journals for publication, once the studies have been completed. The findings will also be shared with clinicians and patients through presentations at information events.

Conclusions: This series of studies is intended to result in an evidence-based decision aid for patients with idiopathic Parkinson disease in order to support the informed and reflected shared decision-making process. We further intend to contribute to a deeper understanding of the individual preferences of patients with idiopathic Parkinson disease and the impact of those preferences on treatment decisions.

(JMIR Res Protoc 2020;9(7):e17482) doi: 10.2196/17482

KEYWORDS
decision aids; Parkinson disease; interview study; online survey; randomized controlled trial; patients
Introduction

Background

Shared decision making has become increasingly common in the context of medical consultations [1-3]. While in any medical consultation it is useful and ethically necessary to inform and educate a patient thoroughly, participatory decisions are particularly appropriate in situations where different alternatives need to be considered and for which no one treatment is superior to the others. In these situations, a preference-sensitive decision should be made based on the personal circumstances and individual preferences of the patient [4-6]. Research indicates that patient participation in the medical decision-making process has positive effects. A meta-analysis [7] with a total of 105 studies showed that shared decision making led to increased knowledge, higher confidence in decisions, and more active patient participation. Studies [7,8] found that the use of shared decision making could reduce health care system costs, because patients often chose less invasive (and therefore, less expensive) treatment options. In addition, most patients would like to be more involved in the medical decision-making process [9]. But, despite these promising findings, shared decision making has not yet been sufficiently implemented in clinical practice [10,11]. The Revised Program Theory for shared decision making [12] identified relevant factors influencing engagement in shared decision making. The authors of that paper [12] explicitly foster future research using this theory and examining additional key mechanisms of shared decision making. Based on these theoretical considerations, herein we will examine the influence of health care system support through decision aids.

Treatment of Parkinson Disease

For the treatment of idiopathic Parkinson disease, both pharmacological and surgical methods can be used. The 2016 Leitlinien für Diagnostik und Therapie in der Neurologie–Idiopathisches Parkinsonsyndrom (Guidelines for Diagnosis and Therapy in Neurology–Idiopathic Parkinson Disease) of the Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (Association of the Scientific Medical Societies) and the Deutsche Gesellschaft für Neurologie (German Society of Neurology) [13] recommended offering subthalamic nucleus–deep brain stimulation to patients with a confirmed diagnosis of idiopathic Parkinson disease who, despite best medical treatments, have motor fluctuations and dyskinesia that cannot be treated with medication, or tremor that cannot be controlled with medication (recommendation 47 in [13]). In addition, deep brain stimulation of the subthalamic nucleus can be offered to patients 60 years of age or younger with confirmed idiopathic Parkinson disease in the first three years after the onset of motor fluctuations or dyskinesia (recommendation 48 in [13]).

Furthermore, it was emphasized that when data suggest deep brain stimulation rather than best medical treatment, surgical treatment should remain an individual decision as long as medical alternatives exist [13]—even if the outcome of drug treatment may be worse than that of subthalamic nucleus–deep brain stimulation in such cases. Nevertheless, since subthalamic nucleus-deep brain stimulation may be more effective than pharmacological treatment, this surgical alternative should be discussed with the patient. When deciding between subthalamic nucleus–deep brain stimulation or drug therapy, patients should be involved in the decision-making process in order to be able to make a preference-sensitive decision with the physician (recommendation 66 in [13]).

Shared Decision Making

Doctors in clinical practice often have too little time for lengthy conversations and tend to overestimate the understanding and health literacy of patients [14,15]. Low health literacy of patients with idiopathic Parkinson disease has been shown to correlate with an increased risk of hospitalization [16]. A meta-analysis showed that the perception of traditional role models, in which doctors are the experts whose instructions are followed, represents a barrier for many patients to actively participating in the decision-making process [17]. One way to deal with this barrier is to use decision aids. They are often used to provide information about illnesses and treatment options and have shown their value in various medical fields [18,19]. Decision guidance is an opportunity to support both patient education and informed decision-making in cooperation with attending physicians and therapists. It is explicitly emphasized that decision aids should not claim to replace patient to doctor direct contact or conversations. Rather, they should be viewed as a supplement that makes it easier to take individual needs into account. The guidelines [13] also recommended that patients with idiopathic Parkinson disease should be provided with individually adapted need-based enhanced communication throughout the course of their disease (recommendation 67 in [13]). According to the Revised Program Theory [12] of shared decision making, giving patients support for shared decision making (for example, by means of a well-designed decision aid) may result in higher confidence in their decision-making abilities and in stronger engagement in shared decision making. Studies [20-22] showed that many patients with Parkinson disease want to play a more active role in treatment decisions [20]. As one study [21] that interviewed patients with Parkinson disease showed, patients often had to take the initiative themselves to be referred to a deep brain stimulation center. Only 10% to 15% of patients for whom deep brain stimulation might be considered a suitable therapy option were, in fact, referred to specialist centers. This finding can be attributed, among other reasons, to insufficient information on the part of patients and neurologists alike [22].

Decision Aids

There are many ways to support patients in their decision-making process and to inform them about the disease and its possible treatment alternatives. Experience reports (ie, narratives) from other patients are an important source of information in addition to exchanges with medical specialists. Patients exchange information about their situation with other people and use the internet in their search for medical information often finding testimonials from other patients [23]. Patient reports are also often integrated into decision-making aids. The use of narratives in decision aids is critically discussed in the literature [24-26]. Narratives have the advantage that they are vivid, easy to understand, and not too abstract, which can
make it easier for patients to process and remember the information conveyed [24,27]; therefore, this format appears to be particularly suitable for patients with idiopathic Parkinson disease, as their cognitive abilities may also be limited. Entwistle et al [28] concluded, in a qualitative interview study, that the personal experiences of others combined with the imparting of factual knowledge can be very helpful for decision making. The patients who were interviewed stated that the reports helped them to better imagine the different options, to become clear about what was important to them personally, and to handle their negative emotions; however, narratives can also have the disadvantage of encouraging the activation of heuristics and generating additional emotions, which can lead to a distorted perception of the information given [25]. In a study [29] with a focus on persuasion, it was found that information mediation with narratives, when compared with scientific information mediation, led to more knowledge gained, more emotions, and stronger persuasion. Narratives also partly influenced the decisions of people who do not have a medical background [30]. In preference-sensitive decision situations, where the needs of the patient should be a key factor in the decision, the persuasive effect of decision support would be considered problematic. The decision-making process of patients should be supported in the preference-sensitive situations that occur in patients with idiopathic Parkinson disease, without convincing them of any one of the possible treatment options. According to the Expected Utility Theory [31,32], it is easier for patients to engage in shared decision making if outcome probabilities of a given treatment are presented. But in preference-sensitive situations, no treatment is superior to the other. As a result, decision difficulty in these situations would be perceived as rather high [12]. The question arises as to whether it makes sense in this situation to report clinical outcomes at all, or whether it is more useful to provide information about possible personal motives and preferences. Decision aids and narratives can be designed very differently and can exert various positive or negative influences on decision making as a result of their design. It is important to understand how decision aids should be designed to help patients take their knowledge, their personal preferences, and their needs into account when making decisions, without pushing them in any specific direction.

**Goals of the Research Project**

In this research project, a series of studies will be conducted to investigate how decision aids for patients with idiopathic Parkinson disease should be designed in order to support the decision-making process. The goal is to support patients in taking their individual preferences into account when making a decision and to make them feel confident with their decision. We will use a participatory design process for the development of the decision aid [33]. Feedback and ideas for improvement will be requested from health care professionals before the prototype is used in the studies.

It is an open question whether the presentation of possible preferences has a positive influence on the decision-making process. In addition, it has not yet been clarified whether patient narratives can strengthen patient decisions in difficult decision situations. Moreover, we will act on the suggestion of the Revised Program Theory and examine additional key mechanisms of shared decision making. We aim to compare the impact of presenting motives that affect a decision with the impact of presenting treatment outcomes.

In Study 1a, qualitative interviews will be conducted to determine which needs frequently occur for patients with idiopathic Parkinson disease. In Study 1b, the identified needs will then be assessed for personal relevance by other patients in an online survey. In Study 2, a randomized controlled trial will be used to pretest different decision aids with people who do not have a medical background and who do not have Parkinson disease. In Study 3, a randomized controlled trial will be used to investigate the effect of the decision aids that were evaluated as positive in Study 2 in patients with idiopathic Parkinson disease.

**Methods**

**Ethical Approval**

These proposed studies have been reviewed and approved by the ethics committee of the Faculty of Medicine of the Eberhard Karls University Tübingen.

**Studies 1a and 1b: Expectations and Wishes Regarding Medical Treatment Options for Parkinson**

**Study Design**

A qualitative interview study (Study 1a) with 6 patients with idiopathic Parkinson disease will identify the common needs, expectations, wishes, and preferences that play a role in the decision to opt for drug-only treatment over deep brain stimulation. Patients with idiopathic Parkinson disease who qualify for deep brain stimulation treatment according to recommendations 47 and 48 in [13] will be invited to a screening week as part of regular clinical care.

During this 1-week inpatient stay, the medical, cognitive, and psychological condition of patients will be examined in preparation for potential deep brain stimulation surgery. From a certain date onward, all patients who meet the inclusion criteria (see below) will be asked by the treating physician whether they agree to participate in a qualitative interview. A semistandardized interview lasting approximately 30 minutes will be conducted with those who agree to participate in order to identify the personal needs, hopes, fears, and expectations associated with drug treatment and deep brain stimulation treatment options. In an online survey study (Study 1b), a different group of patients with idiopathic Parkinson disease will rate the needs, hopes, fears, and expectations that were identified in Study 1a according to personal relevance. Patients with idiopathic Parkinson disease who are at different stages of their disease will be recruited for Study 1b. Patient assessment of their stage and burden of the disease will be measured using a validated questionnaire (Parkinson Disease Questionnaire, PDQ-39) [34].

**Participants**

In order to achieve a representative rating, a total of 60 patients will be recruited for the online survey study (Study 1b). Recruitment will be carried out with the support of the
specialized outpatient units of the University Hospital Tübingen, neurologists in private practice, and self-help groups for patients with idiopathic Parkinson disease. Patients will be included if they have been diagnosed with Parkinson disease, have had Parkinson disease for at least 5 years, are between 18 and 80 years of age; have taken prescribed dopaminergic medication consistently for at least two weeks before inclusion in the study; have a very good knowledge of German, and have signed a written declaration of consent. Patients will be excluded if they have been diagnosed with dementia.

**Study 1a: Interview Guide**

During the interview, each area will be introduced with an open question (Textbox 1). Further questions will follow only if the answer is unclear or the question has not been answered.

**Textbox 1. Open-ended questions and topics for semistructured interview.**

| Satisfaction with the current situation |
|----------------------------------------|
| • How satisfied are you with the current situation? (scaling question: 0 = very dissatisfied, 100 = very satisfied) |
| • What should remain the same? |
| • What should change? |

Other: mobility and motor skills, faculty of speech, sleep, memory and concentration ability, previous treatment, general state of health, execution of profession and hobbies, participation in social life

| Reasons and expectations |
|--------------------------|
| • What are your main reasons for deep brain stimulation? |
| • What are your main reasons for a purely pharmacological therapy? |
| • What are other reasons? |
| • What should change? |
| • How would you know if the decision was good? |
| • In which area (eg, work, social life, hobbies) do you hope to have a positive influence? |
| • What are your plans for the time after the deep brain stimulation/drug changeover? |
| • What positive expectations/worries do you associate with a deep brain stimulation/drug changeover regarding your social environment, your self-reliance, your well-being? |

**Study 1b: Questionnaire**

The needs, wishes, and worries that are identified in Study 1a will be evaluated in Study 1b. Patients who wish to participate will also have to confirm that they are currently in the process of deciding between further treatment with medication or deep brain stimulation. The questionnaire will initially present questions pertaining to inclusion and exclusion criteria, and if their responses indicate they are eligible, questions about personal needs, wishes, and worries will be provided.

A maximum of 20 statements such as (the following are example items only) “I hope to be able to maintain more personal contacts through a successful treatment”, “It is important to me that the treatment has as few side effects as possible,” and “I hope that the treatment will improve my independence” will be evaluated. In addition, participant knowledge about treatment options will be evaluated with maximum of 20 statements or questions such as (the following are example items only) “The danger that deep brain stimulation can lead to psychological impairment is very high” and “The danger that a purely pharmacological treatment can lead to psychological impairment is very high” where participants will indicate whether the statements are true or false and how confident they are in their answers. Since patients with idiopathic Parkinson disease may display neuropsychiatric symptoms, such as apathy or emotional instability, the German version of the Apathy Evaluation Scale [35] and a German version of a short-scale for assessing the personality traits in the five-factor model (big five) [36] will be administered.

**Study 2: Effects of Decision Aids on the Decision-Making Process (People With Nonmedical Background)**

**Study Design**

Based on the patient preferences identified in Study 1, online decision aids will be designed in close collaboration with health professionals. We will use a participatory design process to increase the later acceptance and use of the decision aids, and thus, facilitate the implementation process in clinical practice. The impact of the decision aids on the decision-making process will be investigated in a randomized controlled trial with a 1x3 between-subject design with the following 3 groups: condition 1, decision aid with factual information (control); condition 2, decision aid with factual information and patient reports on the individual motives underlying the decision-making process; and condition 3, decision aid with factual information and patient reports on the outcomes achieved through the treatment option.

In condition 3, positive and negative outcomes will be presented according to the actual success rate of the treatment options, that is, both successful and less successful treatment outcomes will be shown for both treatment options. The information provided to the participants regarding the success rates of the
treatment options will be based upon existing literature in line with institutional history.

We hypothesize that the conditions containing patient reports on motives or outcomes will have a beneficial effect compared to the condition with only factual information; participants to whom decision aids with patient reports are presented will feel better prepared for decision making (Hypothesis 1) and will evaluate the decision more positively (Hypothesis 2). It is an open research question whether the two conditions with patient reports on individual motives and patient reports on outcomes will also differ with respect to preparation for decision making and decision evaluation.

In addition, this study will be used to evaluate and refine the factual information part of the decision aid. Participant knowledge about treatment options will be evaluated pre and posttest to identify which facts are difficult to understand (and which, perhaps, even result in misunderstandings or irrational fears). This information will influence the design of the factual information and will be re-evaluated in the subsequent study (Study 3).

**Participants**

Healthy individuals who are neither active in the medical field nor studying a medical subject will be recruited via the Leibniz Institut für Wissensmedien database of test subjects and the University of Tübingen email distribution list, where individuals who are not studying medical-related subjects can be preidentified. Participants at least 18 years old, not affected by Parkinson disease, and with a very good knowledge of German will be eligible for inclusion.

Since only medium to large effect sizes are relevant for our purposes, a sample size of 37 participants per condition will be targeted. The sample size was determined using G*Power [37] and is based on an alpha error probability of .05, a test power of .90, and an expected effect size of $f=0.30$ for an analysis of variance with repeated measurements and between-subject factors.

**Procedure**

After basic demographic data (age, gender, education) and individual prior experiences with Parkinson disease have been collected, the study participants will be asked to put themselves in the position of a patient with idiopathic Parkinson disease with the help of a case description. The following dependent variables will be measured as target variables before and after the use of the decision support: decisional conflict [38]; hypothetical decision (which treatment option would be preferred); attitude toward both treatment options (modified according to [39]); and knowledge about risks and side effects of treatment options, mode of action of treatment options, and possible advantages and disadvantages of treatment options.

Subsequently, participants will be randomly assigned (computer-generated assignments) to the 3 conditions. Based on the results of Study 1a and Study 1b, a text- and video-based decision aid will be designed with a maximum reception time of 15 minutes.

In addition, the following are to be completed after the decision aid has been used: preparation for decision making (based on [40]); evaluation of the preferences or motives identified in Study 1 with regard to the importance for the decision made, decision evaluation scale [41]; reflection on one’s own reasons for the decision; suggestions for improvement (open answer format), and the knowledge test.

**Measures**

A pre-existing decisional conflict questionnaire will be used [38]. Participants will be asked, “How sure are you about your decision for surgical or non-surgical treatment?” and will reply to three statements using a 7-point Likert scale for each: “It’s hard for me to make that decision”; “I’m not sure how to act on this decision”; “It’s clear which choice is best for me.” They will also be asked “How do you feel about this decision?” and reply to 4 statements using a 7-point Likert scale: “I feel like I made an informed decision”; “My decision shows what is most important to me”; “I expect to stick to my decision”; “I’m satisfied with my decision.” Attitude toward both treatment options will be measured with a 4-item scale (modified following [39]; Figure 1). The knowledge test will be based on the results of Study 1b. The aim will be to provide information on any existing misconceptions or false information regarding the treatment options for Parkinson disease and to test the efficacy of the information provided (a maximum of 10 items). The postintervention preparation for decision making scale is based on [40] (Figure 2). The numerical scale has treatment options ranging from deep brain stimulation on one end of the scale to pure drug therapy on the other end. A decisional conflict questionnaire [38], ratings of feelings about the decision, ratings of attitude toward both treatment options [39], and the decision evaluation scale [41] (Figure 3) will be used.
Figure 1. Attitude toward treatment options.

| Attitude | Deep Brain Stimulation | Parkinson Syndrome |
|----------|------------------------|-------------------|
| Advantageous | □ □ □ □ □ □ □ □ | □ □ □ □ □ □ □ □ |
| Important   | □ □ □ □ □ □ □ □ | □ □ □ □ □ □ □ □ |
| A bad thing | □ □ □ □ □ □ □ □ | □ □ □ □ □ □ □ □ |
| Meaningful  | □ □ □ □ □ □ □ □ | □ □ □ □ □ □ □ □ |

Please indicate how you would personally rate deep brain stimulation:
For me, deep brain stimulation for the treatment of Parkinson syndrome is

| Attitude | Pure Drug Therapy | Parkinson Syndrome |
|----------|-------------------|-------------------|
| Advantageous | □ □ □ □ □ □ □ □ | □ □ □ □ □ □ □ □ |
| Important   | □ □ □ □ □ □ □ □ | □ □ □ □ □ □ □ □ |
| A bad thing | □ □ □ □ □ □ □ □ | □ □ □ □ □ □ □ □ |
| Meaningful  | □ □ □ □ □ □ □ □ | □ □ □ □ □ □ □ □ |

Please indicate how you would personally rate pure drug therapy:
For me, pure drug therapy for the treatment of Parkinson syndrome is

Figure 2. Preparation for decision making scale.

| Help you realize that a decision has to be made? | Not at all | Very much |
|-------------------------------------------------|------------|-----------|
| Prepare you to make a better decision?           | □ □ □ □ □ | □ □ □ □ □ |
| Help you think about the pros and cons of each treatment option? | □ □ □ □ □ | □ □ □ □ □ |
| Help you think about which advantages and disadvantages are most important? | □ □ □ □ □ | □ □ □ □ □ |
| Make it clear to you that your decision depends on what means the most to you? | □ □ □ □ □ | □ □ □ □ □ |
| Help you organize your thoughts about the decision? | □ □ □ □ □ | □ □ □ □ □ |
| Help you think about how much you want to be involved in this decision? | □ □ □ □ □ | □ □ □ □ □ |
| Help you come up with questions you want to ask the doctor? | □ □ □ □ □ | □ □ □ □ □ |
| Prepare you to talk to your doctor about what is most important to you? | □ □ □ □ □ | □ □ □ □ □ |
| Prepare you for your next appointment with your doctor? | □ □ □ □ □ | □ □ □ □ □ |
**Figure 3. Decision evaluation scale.**

| Statement                                                                 | I don't agree at all | I fully agree |
|---------------------------------------------------------------------------|----------------------|---------------|
| I expect to stick to my decision.                                         |                      |               |
| I am satisfied with my decision.                                          |                      |               |
| I still have doubts about my choice.                                     |                      |               |
| This is my own decision.                                                 |                      |               |
| I find it difficult to make that decision.                               |                      |               |
| I am satisfied with the information I have received.                     |                      |               |
| I know the advantages and disadvantages of the treatment methods.        |                      |               |
| I need more information for this decision.                               |                      |               |
| I want clearer advice.                                                   |                      |               |
| I have made a well-informed decision.                                    |                      |               |
| This decision will be made without me.                                   |                      |               |
| I feel pressure from others in this decision.                            |                      |               |
| I wish someone else would decide for me.                                 |                      |               |
| My decision frightens me.                                                |                      |               |
| I regret my decision.                                                    |                      |               |

A maximum of 16 items will be used to evaluate the preferences and motives that were identified in Study 1 with regard to the importance for the decision made such as (the following items are example items only since the items are not yet known): “Please rate the extent to which you agree with the following statements. There is no right or wrong answer. We are only interested in your personal opinion and assessment.”; “The very small, but existing danger of an irreversible side effect (e.g., by a brain hemorrhage) with the deep brain stimulation, influenced my decision strongly.”; “The hope for improvement of my independence in everyday life, through deep brain stimulation, has strongly influenced my decision.”; “The concern about psychological impairment (e.g., psychosis, states of confusion) in a pure drug treatment had a strong influence on my decision.”

**Analysis**

Data analysis will be performed using SPSS statistical software (version 25; IBM Corp). We will perform an analysis of variance with posthoc tests (for interval-scaled data) and Mann-Whitney tests (for ordinal-scaled data). We will report all data as means and standard deviations (for interval-scaled data) and the median (for ordinal-scaled data). The level of significance will be set at $P<.05$. Cohen $d$ and $r$ will be calculated as effect sizes.

**Study 3: Effects of Decision Aids on the Decision-Making Process (Patients With Parkinson Syndrome)**

**Study Design**

Based on the decision aids examined in Study 2, the most suitable format for a preference-sensitive decision will be selected and its efficacy will be compared with that of the use of pure factual information. If the need for further modifications of the decision aids becomes apparent in Study 2, we will implement the modifications in collaboration with health professionals. All of the participating patients will be given the opportunity to use the information material of the other condition immediately after the data collection. This ensures that none of
the study participants will have any disadvantages, despite the randomized between-subject design.

**Participants**

Recruitment will be carried out with the support of the special outpatient units of the University Hospital Tübingen, neurologists in private practices, and Parkinson self-help groups. The same inclusion and exclusion criteria used in Studies 1a and 1b will be used for Study 3. Since, in this case, only medium to large effect strengths ($d = 0.70$) have clinical relevance, a sample size of 36 participants per condition will be targeted.

**Procedure**

Basic demographic data (age, sex, education) and the individual perception of the limitations caused by the disease will be collected with the PDQ-39 [34]. Participants will be asked to complete the following questionnaires before and after the use of the decision support: decisional conflict [38]; hypothetical decision (“which treatment option would you probably choose in this situation?”); attitude toward both treatment options (modifed following [39]); study-designed knowledge test on risks and side effects of treatment options, mode of action of treatment options, possible advantages and disadvantages of treatment options questionnaires will be used. In addition, the following will be completed after the decision aid has been used: preparation for decision making (based on [40]); evaluation of the preferences and motives identified in Study 1 with regard to the importance for the decision made; decision evaluation scale (based on [41]; reflection on one’s own reasons for the decision; suggestions for improvement (open answer format).

**Measures**

Personal assessment of the current stage and burden of the disease will be measured using the validated questionnaire PDQ-39 [28]. Moreover, the German version of the Apathy Evaluation Scale [35] and the German version of the short-scale for assessing the personality traits in the five-factor model (big five) [36] will be used. In addition, all of the scales in Study 2 will be used. Differences will be only in the introduction to the topic (in Study 3 the participants are patients who are actually affected) and the study design. At the end of the study, the participants will also be given the opportunity to use the information material of the other condition.

**Analysis**

Data analysis will be performed using SPSS statistical software (version 25.0; IBM Corp). We will perform $t$ tests (for interval-scaled data) and Mann-Whitney tests (for ordinal-scaled data). We will report all data as means and standard deviations (for interval-scaled data) and as the median (for ordinal-scaled data). The level of significance will be set at $P<.05$. Cohen $d$ and $r$ will be calculated as effect sizes.

**Data Protection**

Personal data will be collected and processed in these studies. For the patients diagnosed with idiopathic Parkinson disease (Studies 1 and 3) the data include their name, sex, age, duration of the disease, other diagnoses, and personal experiences with the disease. In the case of patients, disease data from medical documents (regarding diagnoses and duration of disease) will also be included in the evaluation if necessary. For the medical laypeople (Study 2) the data will include sex, age, and personal experiences with Parkinson disease.

Data will be pseudonymized in a protected electronic database accessible only to authorized staff members, who are bound by professional and data secrecy obligations. In order to verify the correct transfer of the treatment data from the medical file to the encrypted study database, authorized people may inspect the personal disease data related to the study. All employees are bound to secrecy.

The research results from the studies will be published in anonymized form in scientific journals or databases. For the collection, storage, and use of the data, the consent of the participants is required and will be obtained by having them sign the declaration of consent to data protection.

**Results**

This study received ethical approval in January 2020. As of June 2020, data collection for Study 1a has begun, and it is estimated that Studies 1a, 1b, 2, and 3 will take approximately 4, 4, 6, and 6 months to complete, respectively. It is planned to present the study results and analyses at international conferences and to submit them to peer-reviewed journals. The study results will additionally be shared with clinicians and patients by presenting them at information events.

**Discussion**

This series of studies is intended to shed light on how an evidence-based decision aid for patients with idiopathic Parkinson disease should be designed, in order to facilitate an informed and reflected shared decision-making process. Moreover, the series of studies seeks to contribute to a deeper understanding of individual preferences of patients with idiopathic Parkinson disease and the impact of those preferences on treatment decisions. It is idiosyncratic that the decision-process for patients with idiopathic Parkinson disease may take a relatively long period of time (possibly several years). Idiopathic Parkinson disease is a slowly progressing neurodegenerative disease that makes it possible to protract any final decision through a series of continuous re-evaluations of the patients’ current status and reassessments of their quality of life. During this prolonged decision period, evidence and preferences may develop gradually.

The outcomes from this series of studies will provide valuable new insights into the potential of decision aids for supporting a reflective and informed decision about idiopathic Parkinson disease treatment, and the studies will also help to discover barriers to making an informed decision. The findings would be directly applicable to clinical situations such as (1) results about what kind of information is especially misleading can help physicians and therapists to focus on these aspects in their consultations; (2) knowledge about common patient needs, wishes, and fears can help to tailor the given information to individuals, and (3) if the decision aids have been shown to support shared decision making, physicians can use the tools...
as additional support for patients. In this case, the information could potentially be provided before medical consultation as preparation. Physicians could then use the consultation time to respond specifically to patient questions and concerns. It is open for discussion whether the findings of this series of studies could be generalized to other fields and contribute to theory with regard to decision situations where empirical evidence (eg, potential superiority of an invasive therapy) and personal preferences (eg, avoidance of surgical intervention) contradict each other.

The strengths of this series of studies are the combination of research methods (qualitative and quantitative methods), the combination of study settings (field and laboratory studies), the adherence to the Revised Program Theory of shared decision making, and the combination of study populations (patients and healthy participants). These strengths will help to produce a broad and more complete view of decision aids for patients with idiopathic Parkinson disease as well as a deeper insight into principal underlying processes of decision-making.

There are limitations to our studies. One issue is that the significance of any potential findings is restricted to patients who suffer from idiopathic Parkinson disease and have not been diagnosed with dementia. Since the decision aids will target this population, the findings will not be generalizable for patients with other diagnoses. Our studies will aim to explore the presentation of motives and outcomes regarding shared decision making for patients with idiopathic Parkinson disease, so we will not be able to make recommendations on how to design and implement other decision support systems in different contexts. Nevertheless, the fine-grained participatory procedure applied here for the design and evaluation of decision aids can also be used for designing decision aids in other contexts or systems. An in-depth analysis of patient state of knowledge, needs, wishes, and fears before designing a support system would streamline the design process.

Acknowledgments
The research reported here will be supported by budgeted resources of the Leibniz-Institut für Wissensmedien and the University of Tübingen.

Conflicts of Interest
For authors MB, JK, ME, IC, none declared. AG was supported by research grants from Medtronic, Abbott, Boston Scientific, the German Federal Ministry of Education and Research, and the Baden-Württemberg Foundation. DW was supported by research grants from Medtronic, Abbott, Boston Scientific, German Research Council, and travel grants and speakers’ honoraria from Medtronic, Abbott, Boston Scientific, Abbvie, STADA, Bial. The funding had no involvement in study design, the writing of the report, and in the decision to submit the article for publication.

References
1. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med 1997 Mar;44(5):681-692. [Medline: 9032835]
2. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. J Gen Intern Med 2012 Oct;27(10):1361-1367 [FREE Full text] [doi: 10.1007/s11606-012-2077-6] [Medline: 22618581]
3. Eggeling M, Bientzle M, Cress U, Shiozawa T, Kimmerle J. The impact of physicians' recommendations on treatment preference and attitudes: a randomized controlled experiment on shared decision-making. Psychol Heal Med 2020 Mar;25(3):259-269. [doi: 10.1080/13548506.2019.1687917] [Medline: 31707838]
4. Keirns CC, Goold SD. Patient-centered care and preference-sensitive decision making. JAMA 2009 Oct 28;302(16):1805-1806. [doi: 10.1001/jama.2009.1550] [Medline: 19861674]
5. Elwyn G, Frosch D, Rollnick S. Dual equipoise shared decision making: definitions for decision and behaviour support interventions. Implement Sci 2009 Nov 18;4:75 [FREE Full text] [doi: 10.1186/1748-5908-4-75] [Medline: 19922647]
6. Weroff D, Marr A, Wennberg DE. Enhanced support for shared decision making reduced costs of care for patients with preference-sensitive conditions. Health Affairs 2013 Feb;32(2):285-293. [doi: 10.1377/hlthaff.2011.0941]
7. Stacey D, Légaré F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2017 Dec 12;4:CD001431. [doi: 10.1002/14651858.CD001431.pub5] [Medline: 28402085]
8. Oshima LE, Emanuel EJ. Shared decision making to improve care and reduce costs. N Engl J Med 2013 Jan 03;368(1):6-8. [doi: 10.1056/NEJMip1209500] [Medline: 23281971]
9. Chewning B, Bylund CL, Shah B, Arora NK, Gueguen JA, Makoul G. Patient preferences for shared decisions: a systematic review. Patient Educ Couns 2012 Jan;86(1):9-18 [FREE Full text] [doi: 10.1016/j.pec.2011.02.004] [Medline: 21474265]
10. Kayyali R, Gebara SN, Hesso I, Funnell G, Naik M, Mason T, et al. Shared decision making and experiences of patients with long-term conditions: has anything changed? BMC Health Serv Res 2018 Oct 10;18(1):763 [FREE Full text] [doi: 10.1186/s12913-018-3575-y] [Medline: 30305085]
11. Ford S, Schofield T, Hope T. Are patients' decision-making preferences being met? Health Expect 2003 Mar;6(1):72-80 [FREE Full text] [doi: 10.1046/j.1369-6513.2003.00211.x] [Medline: 12603630]
12. Waldron T, Carr T, McMullen L, Westhorp G, Duncan V, Neufeld S, et al. Development of a program theory for shared decision-making: a realist synthesis. BMC Health Serv Res 2020 Jan 23;20(1):59 [FREE Full text] [doi: 10.1186/s12913-019-4649-1] [Medline: 31973754]

13. Arbeitsgemeinschaft D. Leitlinien für Diagnostik und Therapie in der Neurologie - Idiopathisches Parkinsonsyndrom. Available. URL: https://www.awmf.org/uploads/tx_szleitlinien/030-010l_S3_Parkinson_Syndrome_Idiopathisch_2016-06.pdf [accessed 2020-06-15]

14. Weinman J, Yusuf G, Berks R, Rayner S, Petrie KJ. How accurate is patients' anatomical knowledge: a cross-sectional, questionnaire study of six patient groups and one professional group. BMC Fam Pract 2009 Jun 12;10:43 [FREE Full text] [doi: 10.1186/1471-2296-10-43] [Medline: 19523189]

15. Cosic F, Kimmel L, Edwards E. Patient comprehension of common orthopedic terminology. Health Lit Res Pract 2019 Jul;3(3):e187-e193 [FREE Full text] [doi: 10.3928/24748307-20190624-04] [Medline: 31428736]

16. Fleisher JE, Shah K, Fitts W, Dahodwala NA. Associations and implications of low health literacy in Parkinson's Disease. Mov Disord Clin Pract 2016;3(3):250-256 [FREE Full text] [doi: 10.1002/mdc3.12272] [Medline: 27331078]

17. Joseph-Williams N, Elwyn G, Edwards A. Knowledge is not power for patients: a systematic review and thematic synthesis of patient-reported barriers and facilitators to shared decision making. Patient Educ Couns 2014 Mar;94(3):291-309. [doi: 10.1016/j.pec.2013.10.031] [Medline: 24305642]

18. Scalia P, Durand MA, Berkowitz JL, Ramesh NP, Faber MJ, Kremer JAM, et al. The impact and utility of encounter patient decision aids: systematic review, meta-analysis and narrative synthesis. Patient Educ Couns 2019 May;102(5):817-841. [doi: 10.1016/j.pec.2018.12.020] [Medline: 30612829]

19. Eggelings M, Bientzle M, Shiozawa T, Cress U, Kimmerle J. The impact of visualization format and navigational options on laypeople’s perception and preference of patient information videos: randomized controlled trial and online survey. J Participat Med 2018 Nov 22;10(4):e12338. [doi: 10.2196/12338]

20. Weernink MGM, van Til JA, van Vugt JPP, Movig KLL, Groothuis-Oudshoorn CGM, IJzerman MJ. Involving patients in weighting benefits and harms of treatment in Parkinson's disease. PLoS One 2016;11(8):e0160771 [FREE Full text] [doi: 10.1371/journal.pone.0160771] [Medline: 27575744]

21. Hamberg K, Hariz G. The decision-making process leading to deep brain stimulation in men and women with parkinson's disease - an interview study. BMC Neurol 2014 Apr 25;14:89 [FREE Full text] [doi: 10.1186/1471-2377-14-89] [Medline: 24761767]

22. Lange M, Mauerer J, Schlaier J, Janzen A, Zeman F, Bogdahn U, et al. Underutilization of deep brain stimulation for Parkinson's disease? a survey on possible clinical reasons. Acta Neurochir (Wien) 2017 May;159(5):771-778. [doi: 10.1007/s00701-017-3122-3] [Medline: 28258308]

23. Kimmerle J, Bientzle M, Cress U. Personal experiences and emotionality in health-related knowledge exchange in internet forums: a randomized controlled field experiment comparing responses to facts vs personal experiences. J Med Internet Res 2014 Dec 04;16(12):e277 [FREE Full text] [doi: 10.2196/jmir.3766] [Medline: 25486677]

24. Bekker HL, Winterbottom AE, Butow P, Dillard AJ, Feldman-Stewart D, Fowler FJ, et al. Do personal stories make patient decision aids more effective? a critical review of theory and evidence. BMC Med Inform Decis Mak 2013;13 Suppl 2:S9 [FREE Full text] [doi: 10.1186/1472-6947-13-S2-S9] [Medline: 24625283]

25. Winterbottom A, Bekker HL, Conner M, Mooney AF. Does narrative information bias individual's decision making? a systematic review. Soc Sci Med 2008 Dec;67(12):2079-2088. [doi: 10.1016/j.socscimed.2008.09.037] [Medline: 18951673]

26. Osaka W, Nakayama K. Effect of a decision aid with patient narratives on reducing decisional conflict in choice for surgery among early-stage breast cancer patients: a three-arm randomized controlled trial. Patient Educ Couns 2017 Mar;100(3):550-562. [doi: 10.1016/j.pec.2016.09.011] [Medline: 28277290]

27. Mazor KM, Baril J, Dugan E, Spencer F, Burgwinkle P, Gurwitz JH. Patient education about anticoagulant medication: is narrative evidence or statistical evidence more effective? Patient Educ Couns 2007 Dec;69(1-3):145-157. [doi: 10.1016/j.pec.2007.08.010] [Medline: 17942268]

28. Entwistle VA, France EF, Wyke S, Jepson R, Hunt K, Ziebland S, et al. How information about other people's personal experiences can help with healthcare decision-making: a qualitative study. Patient Educ Couns 2011 Dec;85(3):e291-e298. [doi: 10.1016/j.pec.2011.05.014] [Medline: 21652162]

29. Betsch C, Ulshöfer C, Renkewitz F, Betsch T. The influence of narrative vs. statistical information on perceiving vaccination risks. Med Decis Making 2011;31(5):742-753. [doi: 10.1177/0272989X11400419] [Medline: 21447730]

30. Winterbottom AE, Bekker HL, Conner M, Mooney AF. Patient stories about their dialysis experience biases others' choices regardless of doctor's advice: an experimental study. Nephrol Dial Transplant 2012 Jan;27(1):325-331. [doi: 10.1093/ndt/gfr266] [Medline: 21642512]

31. Tversky A. A critique of expected utility theory: descriptive and normative considerations. Erkenntnis 1975 Jun;9(2):163-173. [doi: 10.1007/bf00226380]

32. Briggs R. Normative theories of rational choiceexpectedutility. The Stanford Encyclopedia of Philosophy (edition Fall 2019;Edward N. Zalta (ed.). Available:E [FREE Full text]
33. Al-Itejawi HHM, van UCF, Vis AN, Nieuwenhuijzen JA, Hofstee MJA, van MRJA, et al. Development of a patient decision aid for the treatment of localised prostate cancer: a participatory design approach. J Clin Nurs 2016 Apr;25(7-8):1131-1144. [doi: 10.1111/jocn.13120] [Medline: 26880526]

34. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score. Age Ageing 1997 Sep;26(5):353-357. [Medline: 9351479]

35. Luken U, Seidl U, Schwarz M, Völker L, Naumann D, Mattes K, et al. Psychometric properties of a German version of the Apathy Evaluation Scale. Fortschr Neurol Psychiatr 2006 Dec;74(12):714-722. [doi: 10.1055/s-2006-932164] [Medline: 17167730]

36. Rammstedt B, Kemper C, Klein M, Beierlein C, Kovaleva A. A short scale for assessing the big five dimensions of personality: Big Five Inventory (BFI-10). MDA 2013;7(2):10. [doi: 10.12758/mda.2013.013]

37. Faul F, Erdfelder E, Lang A, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007 May;39(2):175-191. [Medline: 17695343]

38. O'Connor AM. Validation of a decisional conflict scale. Med Decis Making 1995;15(1):25-30. [Medline: 7898294]

39. Marteau TM, Dormandy E, Michie S. A measure of informed choice. Health Expect 2001 Jun;4(2):99-108. [Medline: 11359540]

40. Bennett C, Graham ID, Kristjansson E, Kearing SA, Clay KF, O'Connor AM. Validation of a preparation for decision making scale. Patient Educ Couns 2010 Jan;78(1):130-133. [doi: 10.1016/j.pec.2009.05.012] [Medline: 19560303]

41. Stalmeier PFM, Roosmalen MS, Verhoef LCG, Hoekstra-Weebers JEHM, Oosterwijk JC, Moog U, et al. The decision evaluation scales. Patient Educ Couns 2005 Jun;57(3):286-293. [doi: 10.1016/j.pec.2004.07.010] [Medline: 15893210]

Abbreviations

PDQ: Parkinson Disease Questionnaire